NASDAQ$TMDX
TransMedics Group Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
TransMedics' first quarter results for 2022 showed significant revenue growth driven by the National OCS Program.
TransMedics reported a strong first quarter with net revenue of $15.9 million, a 125% increase compared to the same period in 2021. The growth was primarily driven by increased commercial sales of OCS Heart and OCS Liver in the United States. The company is updating its full year 2022 net revenue guidance to be in the range of $59 million to $65 million.
- Net revenue reached $15.9 million, marking a 125% increase compared to Q1 2021.
- FDA pre-market approval was received for the OCS™ DCD heart indication on April 28, 2022.
- Data from the U.S. randomized OCS™ DCD Heart trial and OCS™ Lung Trial 5-year data were presented at the International Society of Heart and Lung Transplantation (ISHLT) annual meeting.
- The National OCS™ Program (NOP) was the primary growth driver.
Headline financials
Revenue & EPS history
TransMedics · Revenue · Quarterly
$15.9M
Forward guidance
TransMedics is updating full year 2022 net revenue to be in the range of $59 million to $65 million, which represents 95% to 115% growth compared to the company’s prior year net revenue.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+4.1%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+7.6%
Avg return
30 days after
54%
15 / 28 earnings
Positive
+42.6%
Q3 2023
Best reaction
-29.3%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.1% | -30.0% | -26.4% | |
| Q4 2025 | -4.6% | -3.6% | -35.1% | |
| Q3 2025 | +0.9% | -9.0% | +8.9% | |
| Q1 2025 | +19.6% | +31.3% | +49.2% | |
| Q4 2024 | +5.8% | -6.5% | -4.9% | |
| Q3 2024 | -29.3% | -34.2% | -30.4% | |
| Q2 2024 | +9.4% | +7.2% | +21.4% | |
| Q1 2024 | +20.9% | +31.6% | +40.3% | |
| Q4 2023 | +6.7% | -0.5% | -10.8% | |
| Q3 2023 | +42.6% | +34.6% | +73.5% | |
| Q2 2023 | -8.9% | -24.7% | -21.5% | |
| Q1 2023 | -6.7% | -6.4% | -8.1% | |
| Q4 2022 | +20.2% | +20.4% | +15.4% | |
| Q3 2022 | +20.7% | +17.6% | +38.7% | |
| Q2 2022 | -7.7% | +20.8% | +28.9% | |
| Q1 2022 | +39.5% | +25.4% | +29.5% | |
| Q4 2021 | +23.2% | +39.5% | +82.5% | |
| Q3 2021 | -12.0% | -16.3% | -29.0% | |
| Q2 2021 | +9.6% | +7.6% | +17.2% | |
| Q1 2021 | -12.6% | -15.1% | -11.3% | |
| Q4 2020 | +3.4% | -12.3% | +10.6% | |
| Q3 2020 | +4.8% | +10.6% | +20.8% | |
| Q2 2020 | +0.1% | -3.2% | -11.9% | |
| Q1 2020 | -7.6% | -0.6% | -11.7% | |
| Q4 2019 | -1.1% | -1.2% | -25.7% | |
| Q3 2019 | -14.2% | -13.0% | -1.7% | |
| Q2 2019 | -4.2% | -4.6% | +8.6% | |
| Q1 2019 | -2.3% | -2.1% | -4.1% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro